Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    enGene Inc. Common Stock

    NASDAQ: ENGN · Real-Time Price · USD
    4.13
    -0.16 (-3.73%)
    At close: May 23, 2025, 3:59 PM
    4.24
    2.66%
    After-hours: May 23, 2025, 04:04 PM EDT
    -3.73%
    Bid 3.93
    Market Cap 210.92M
    Revenue (ttm) n/a
    Net Income (ttm) -69.05M
    EPS (ttm) -1.48
    PE Ratio (ttm) -2.79
    Forward PE -1.94
    Analyst Buy
    Ask 4.33
    Volume 42,754
    Avg. Volume (20D) 57,846
    Open 4.01
    Previous Close 4.29
    Day's Range 4.01 - 4.34
    52-Week Range 2.65 - 13.00
    Beta -0.35

    About ENGN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ENGN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ENGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 months ago
    +1.19%
    EnGene Holdings shares are trading higher after Pi... Unlock content with Pro Subscription
    7 months ago
    +1.91%
    EnGene Holdings shares are trading higher. The company announced it generated approximately $60 million in proceeds from a private placement.
    news image

    3 weeks ago · businesswire.com

    enGene to Participate in Upcoming Investor Conferences

    BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will presen...

    news image

    1 month ago · businesswire.com

    enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity...

    news image

    1 month ago · businesswire.com

    enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

    BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Exec...

    news image

    2 months ago · businesswire.com

    enGene Reports First Quarter 2025 Financial Results and Provides Business Update

    BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for ...

    news image

    2 months ago · seekingalpha.com

    enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

    enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene vorapl...

    Add to Watchlist